Table 2. Multivariate analyses of prognostic factors for patients receiving chemotherapy only.
| Factors | PFS | OS | |||||
|---|---|---|---|---|---|---|---|
| HR | 95% CI | p-value | HR | 95% CI | p-value | ||
| Platinum resistance (SPR vs. PPR) | 0.74 | 0.57–0.97 | 0.029 | 0.85 | 0.64–1.12 | 0.235 | |
| Study group vs. TRIAS | 0.804 | 0.481 | |||||
| TOWER | 1.08 | 0.81–1.44 | 0.84 | 0.62–1.13 | |||
| NOGGO | 0.97 | 0.67–1.42 | 0.95 | 0.65–1.39 | |||
| Age at randomization (≥60 vs. <60 years) | 1.01 | 0.77–1.32 | 0.964 | 1.02 | 0.76–1.35 | 0.910 | |
| CA-125 (≥100 vs. <100 IU/mL) | 1.27 | 0.97–1.66 | 0.082 | 1.34 | 1.02–1.77 | 0.037 | |
| Presence of ascites at study inclusion (yes vs. no) | 1.12 | 0.88–1.43 | 0.350 | 1.77 | 1.39–2.27 | <0.001 | |
| ECOG (1/2 vs. 0) | 1.10 | 0.85–1.43 | 0.465 | 1.40 | 1.08–1.83 | 0.012 | |
Investigation of the independent significance for prognostic factors regarding PFS and OS in the overall cohort excluding patients who received sorafenib within TRIAS (n=394).
CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; OS, overall survival; PFS, progression-free survival; PPR, primary platinum-resistant; SPR, secondary platinum-resistant.